Hypera (HYPE3) investor relations material

Executive summary

• Q3 net revenue rose 9.4% YoY to R$2,435.8m; continuing-operations net income increased 16.1% to R$527.0m.

• Retail sell-out grew 6.6%, 1.2pp ahead of growth in served categories; Semavy’s September launch supported expansion into injectable GLP-1 analogues.

• Net debt declined R$293.4m QoQ to R$5,610.1m, or 2.0x LTM continuing-operations EBITDA.

Financial highlights

• Q3 gross profit rose 9.7% YoY to R$1,493.7m; gross margin was 61.3%, versus 61.2% a year earlier.

• Continuing-operations EBITDA increased 3.4% to R$782.3m; EBITDA margin fell 1.9pp to 32.1% as marketing and sales costs grew faster than revenue.

• Continuing-operations net income was R$527.0m; consolidated net income was R$523.2m, including a R$3.8m loss from discontinued operations.

• 9M revenue rose 24.3% to R$6,790.3m, gross profit increased 31.0% to R$4,148.0m, and continuing-operations EBITDA grew 59.3% to R$2,123.7m.

• Marketing expenses were R$414.7m and selling expenses R$272.2m; G&A expenses were R$93.4m and unchanged as a share of revenue.

Outlook and guidance

• October sell-out was expected to grow at a low-teens rate; Semavy was the leading contributor and was expected to lead growth through end-2027.

• September Semavy sell-out was ~94,000 units; October volume was expected to double, with supply planning focused on avoiding stockouts.

• 2027 CapEx was expected to decline as major projects conclude, though some spending may shift into Q1 2027.

• Institutional-market sales target of R$1.5bn, initially aimed for 2028, may be reached closer to 2030 because of Anvisa approval delays.

• Management expected to approach 1.5x net debt/EBITDA by end-2027, before shareholder payouts or further investment.